I think it would be only too logical to check lowering prices against comparable countries, and that would have no impact on research and development funding.
For example, in terms of the money we could save, we have to understand how the whole current innovation system works in the pharmaceutical sector; the system is based on commercialization by the major dominant companies that we have talked about. For example, the main goal of any biotechnology company is to be bought by one of those dominant players.
The problem is that dominant companies have a research agenda that relies on me-too drugs. But there is a way to improve therapeutic innovation. I think the way to do that is to have public research. There should be an alternative business model, based more so on public research than commercialization by large corporations. That model would not replace what is being done, but it would complement the work nicely by potentially bringing something new and something different to the current pharmaceutical sector.